Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract. 2021 Jan 13;:
Authors: Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M
BACKGROUND: Dupilumab has demonstrated efficacy with acceptable safety in clinical trials in patients with moderate-to-severe atopic dermatitis (AD).
OBJECTIVE: To assess dupilumab's impact on asthma and sinonasal conditions in adult patients with moderate-to-severe AD in 4 randomized, double-blinded, placebo-controlled trials.
METHODS: In LIBERTY AD SOLO 1 (NCT02277743), SOLO 2 (NCT02755649), CHRONOS (NCT02260986), and CAFÉ (NCT02755649), patients received placebo, dupilumab 300 mg every 2 weeks (q2w), or dupilumab 300 mg weekly (qw). In CHRONOS and CAFÉ, patients received concomitant topical corticosteroids. This post hoc analysis assessed Asthma Control Questionnaire-5 (ACQ-5) scores in patients with asthma, Sino-Nasal Outcome Test-22 (SNOT-22) scores in patients with sinonasal conditions, and AD signs and symptoms in all patients.
RESULTS: Of the 2,444 patients, 463 (19%) had asthma with baseline ACQ-5 ≥ 0.5; 1,171 (48%) had sinonasal conditions; and 311 (13%) had both. At Week 16, ACQ-5 scores improved by (least squares mean change from baseline [standard error]) 0.27 (0.07), 0.59 (0.08), and 0.56 (0.07) in placebo-, q2w-, and qw-treated patients with asthma, respectively, while SNOT-22 scores improved by 5.1 (0.8), 9.9 (0.9), and 10.8 (0.8) in patients with sinonasal conditions (P<.01 for all dupilumab vs placebo). Improvements in ACQ-5 and SNOT-22 were also seen in patients with both conditions. Dupilumab also significantly improved AD signs and symptoms among all subgroups.
CONCLUSION: In this first analysis of patients with comorbid moderate-to-severe AD, asthma, and/or chronic sinonasal conditions, dupilumab improved all 3 diseases in a clinically meaningful and statistically significant (vs placebo) manner, based on validated outcome measures.
PMID: 33453450 [PubMed - as supplied by publisher]